Nimbus Nips At BMS’s Heels With Psoriasis Results For TYK2 Inhibitor

 
• By Alaric DeArment

Without disclosing data, Nimbus announced positive Phase IIb results for NDI-034858 in psoriasis. The company plans to initiate a Phase III trial next year.

Nimbus announced positive results from its Phase IIb study of NDI-034858 • Source: Shutterstock

More from Clinical Trials

More from R&D